Literature DB >> 20473205

Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects.

Sherrie H Kaplan1, John Billimek, Dara H Sorkin, Quyen Ngo-Metzger, Sheldon Greenfield.   

Abstract

BACKGROUND: Interest in comparative effectiveness research and the rising number of negative or "small effect" trials have stimulated research into differential response to treatment among subgroups of patients.
OBJECTIVE: To develop and test the Potential for Benefit Scale (PBS), a composite measure to identify subgroups of patients with differential potential for response to treatment, using diabetes as a model.
DESIGN: Cross-sectional and longitudinal cohort study. SUBJECTS AND
SETTING: Type 2 diabetes patients (n = 1361) were identified from 7 outpatient clinics serving a diverse population. Of these, 611 completed a 1-year follow-up. MEASURES: To represent patients' health status, we used the Total Illness Burden Index, the Physical Function Index of the SF-36, the Center for Epidemiologic Studies Depression Scale, and the Diabetes Burden Scale. To represent personality characteristics related to health, we used the Provider-Dependent Health Care Orientation scale. We assessed the contribution of these measures to a composite scale of patients' potential for treatment response in terms of self-reported medication adherence and glycemic control.
RESULTS: Principal components analysis confirmed associations among these measures. The internal consistency reliability of the PBS was adequate (Cronbach alpha = 0.65). Patients in the lowest versus highest quartile of the PBS reported poorer adherence (18% vs. 55%, P < 0.001) and poorer glycemic control at baseline (mean hemoglobin A1c values: 7.75 vs. 7.39, P < 0.001). Those in the highest quartile of the PBS also were more likely to reach target values for glycemic control (HbA1c <7%) at 1-year follow-up, (adjusted OR = 1.61, P < 0.05).
CONCLUSIONS: The PBS, a composite scale, may be helpful in identifying patients with differential potential for response to treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473205      PMCID: PMC5769476          DOI: 10.1097/MLR.0b013e3181d99161

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  48 in total

Review 1.  Translating social ecological theory into guidelines for community health promotion.

Authors:  D Stokols
Journal:  Am J Health Promot       Date:  1996 Mar-Apr

2.  The sense of mastery as a mediator and moderator in the association between economic hardship and health in late life.

Authors:  Tetyana Pudrovska; Scott Schieman; Leonard I Pearlin; Kim Nguyen
Journal:  J Aging Health       Date:  2005-10

3.  Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.

Authors:  David M Kent; Rodney A Hayward
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

4.  Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.

Authors:  Richard L Kravitz; Naihua Duan; Joel Braslow
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

5.  What can we do to improve physical function in older persons with type 2 diabetes?

Authors:  L B Caruso; R A Silliman; S Demissie; S Greenfield; E H Wagner
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-07       Impact factor: 6.053

6.  Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice.

Authors:  Mark S Litwin; Sheldon Greenfield; Eric P Elkin; Deborah P Lubeck; Jeanette M Broering; Sherrie H Kaplan
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

7.  Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study.

Authors:  Sheldon Greenfield; John Billimek; Fabio Pellegrini; Monica Franciosi; Giorgia De Berardis; Antonio Nicolucci; Sherrie H Kaplan
Journal:  Ann Intern Med       Date:  2009-12-15       Impact factor: 25.391

8.  Depressive symptomatology mediates the effect of socioeconomic disadvantage on HbA(1c) among rural African Americans with type 2 diabetes.

Authors:  Steven M Kogan; Gene H Brody; Yi-Fu Chen
Journal:  J Psychosom Res       Date:  2009-04-01       Impact factor: 3.006

Review 9.  The uses of outcomes research for medical effectiveness, quality of care, and reimbursement in type II diabetes.

Authors:  S Greenfield; S H Kaplan; R A Silliman; L Sullivan; W Manning; R D'Agostino; D E Singer; D M Nathan
Journal:  Diabetes Care       Date:  1994-06       Impact factor: 19.112

10.  Personal control and coronary artery disease: how generalized expectancies about control may influence disease risk.

Authors:  T E Seeman
Journal:  J Psychosom Res       Date:  1991       Impact factor: 3.006

View more
  16 in total

1.  Heterogeneity in action: the role of passive personalization in comparative effectiveness research.

Authors:  Anirban Basu; Anupam B Jena; Dana P Goldman; Tomas J Philipson; Robert Dubois
Journal:  Health Econ       Date:  2013-10-09       Impact factor: 3.046

2.  Support and influence in the context of diabetes management: do racial/ethnic differences exist?

Authors:  Kristin J August; Dara H Sorkin
Journal:  J Health Psychol       Date:  2011-03-28

3.  Patient-centered or 'central' patient: Raising the veil of ignorance over randomization.

Authors:  Anirban Basu
Journal:  Stat Med       Date:  2012-11-10       Impact factor: 2.373

4.  Contributors to Patients' Ratings of Quality of Care Among Ethnically Diverse Patients with Type 2 Diabetes.

Authors:  Sarah E Choi; Quyen Ngo-Metzger; John Billimek; Sheldon Greenfield; Sherrie H Kaplan; Dara H Sorkin
Journal:  J Immigr Minor Health       Date:  2016-04

5.  Using meta-analyses for comparative effectiveness research.

Authors:  Vicki S Conn; Todd M Ruppar; Lorraine J Phillips; Jo-Ana D Chase
Journal:  Nurs Outlook       Date:  2012 Jul-Aug       Impact factor: 3.250

6.  Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study.

Authors:  Daniel A Barocas; Vivien Chen; Matthew Cooperberg; Michael Goodman; John J Graff; Sheldon Greenfield; Ann Hamilton; Karen Hoffman; Sherrie Kaplan; Tatsuki Koyama; Alicia Morgans; Lisa E Paddock; Sharon Phillips; Matthew J Resnick; Antoinette Stroup; Xiao-Cheng Wu; David F Penson
Journal:  J Comp Eff Res       Date:  2013-07       Impact factor: 1.744

7.  Patient complexity and risk factor control among multimorbid patients with type 2 diabetes: results from the R2D2C2 study.

Authors:  Shaista Malik; John Billimek; Sheldon Greenfield; Dara H Sorkin; Quyen Ngo-Metzger; Sherrie H Kaplan
Journal:  Med Care       Date:  2013-02       Impact factor: 2.983

8.  Do pre-existing diabetes social support or depressive symptoms influence the effectiveness of a diabetes management intervention?

Authors:  Ann-Marie Rosland; Edith Kieffer; Michael Spencer; Brandy Sinco; Gloria Palmisano; Melissa Valerio; Emily Nicklett; Michele Heisler
Journal:  Patient Educ Couns       Date:  2015-06-05

9.  Reducing racial/ethnic disparities in diabetes: the Coached Care (R2D2C2) project.

Authors:  Sherrie H Kaplan; John Billimek; Dara H Sorkin; Quyen Ngo-Metzger; Sheldon Greenfield
Journal:  J Gen Intern Med       Date:  2013-10       Impact factor: 5.128

10.  Distinguishing Selection Bias and Confounding Bias in Comparative Effectiveness Research.

Authors:  Sebastien Haneuse
Journal:  Med Care       Date:  2016-04       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.